Denmark· DK-28105938917
Prevymis
A letermovir product containing letermovir, registered in Denmark by Merck Sharp & Dohme B.V.. The same ATC class is registered in 15 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Letermovir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX18 (letermovir), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Letermovir · ATC J05AX18
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of letermovir costs, country by country.
Normalised to the WHO defined daily dose (0.48 g), the median price runs from $9.77 in France to $563.69 in Italy — a ×58 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Letermovir · price per daily dose (0.48 g)
USD · FX 28 Sept 2026
- IT Italy$563.69
- CH Switzerland$371.41
- FR France$9.77
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Letermovir
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Denmark (DK)
- ATC code
- J05AX18
- ATC class
- Letermovir
- Defined daily dose
- 0.48 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105938917
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
222 interactions on record for letermovir.
Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Letermovir · interactions on record
222 records
- 38 severe
- 172 moderate
- 12 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- CilostazolB01AC23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J05AX18
Letermovir, as other registers publish it.
- PolandPrevymisMerck Sharp & Dohme B.V.
- DenmarkPrevymisMerck Sharp & Dohme B.V.
- PolandPrevymisMerck Sharp & Dohme B.V.
- DenmarkPrevymisMerck Sharp & Dohme B.V.
- PolandPrevymisMerck Sharp & Dohme B.V.
- DenmarkPrevymisMerck Sharp & Dohme B.V.
- PolandPrevymisMerck Sharp & Dohme B.V.
- IcelandPrevymisMerck Sharp & Dohme B.V.*
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df4bef2a-5684-490b-9dfe-4ac1a3d1ebd5 GET /v1/drugs/df4bef2a-5684-490b-9dfe-4ac1a3d1ebd5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "240 mg",
"auth_role": "CO-RAP",
"dk_drugid": "28105938917",
"substance": "Letermovir",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "43108"
}See everything about letermovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.